Conference Day One
Wednesday 26th February 2025
8:00 am Morning Check in & Coffee
8:50 am Chair’s Opening Remarks
Understanding Unique Characteristics of an Optimal Radiopharmaceutical Target to Guide Ideal Selection
9:00 am Panel Discussion: Investigating Attributes of a Prime Radiopharmaceutical Target to Match the Properties of a Radioactive Drug
Synopsis
- Considering receptor density, expression levels and radiosensitive tissues
- Analyzing alpha vs beta emitter target requirements for optimal strategy
- Assessing stromal targeting such as FAP or internalized targets
9:30 am uPAR: A Promising Novel Radiopharmaceutical Target for Solid Tumors
Synopsis
- Revealing why uPAR is a promising radiopharma target and what characteristics make it particularly appealing
- Sharing the strategy that went into creating Monopar’s targeting agent against uPAR
- Optimizing biodistribution preclinically and how that translated
10:00 am Disclosing Novel Radiopharmaceutical Therapeutic Target Beyond Current Pipeline
Synopsis
- Identifying key target attributes
- Revealing targeting strategies
- Uncovering early preclinical data
10:30 am Speed Networking & Morning Coffee Break
Mining New Radiopharmaceutical Targets for Novel Therapeutics to Differentiate Your Pipeline
11:30 am Leveraging Novel Proteogenomic Approaches & Machine Learning to Accelerate Radioconjugate Target Discovery
Synopsis
- Identifying and validating therapeutic targets using surface proteomics and tailored data analytics
- Integration of surface proteomics into proteogenomic computational methods to enhance target selection paired with patient, disease and drug biology
- Exploring the “deep proteome” and other proteomic data types to unlock novel target space
12:00 pm Unveiling Key Regulatory Elements of the TGFB-LRRC15 Axis Through Advanced High-Throughput Screening Methodologies
Synopsis
- Uncovering TGFβ)-driven and LRRC15+ signature associated immunotherapy resistance
- Targeting LLRC15 for therapeutic and imaging
- Overcoming radio resistance through enhanced mechanistic understandings
12:30 pm Lunch Break & Networking
Selecting Characterized & Novel Targets for Use with Radiopharmaceutical Candidates to Address Unmet Medical Need
1:30 pm Fireside: Paving the Path for Novel Radiopharmaceutical Targets or Following Bonified ADC Targets: Advantages & Pitfalls
Synopsis
- Leveraging established ADC Targets for radiopharmaceuticals for well characterized mechanism of action such as NECTIN-4
- Identifying and pursuing untapped biological targets to revolutionize radiopharmaceuticals such as failed ADC targets
- Commercial considerations to balance risks and hurdles
2:00 pm Revealing Novel Radioimmunotherapy Targeting B7-H3 for Solid Tumors
Synopsis
- Targeting the immune checkpoint protein selectively expressed
- Understanding the complex tumor microenvironment
- Delivering localized radiation
2:30 pm Strategy & Rationale Behind Selection of RPT Targets: Case Studies with GPC3 & CAIX
Synopsis
- Designing novel radiopharmaceutical drugs with precision
- Sharing design choices for enhanced efficacy
- Revealing new directions with novel target
3:00 pm Afternoon Coffee Break & Networking
Rational Drug Design for Radiopharmaceuticals: Cutting-Edge Targeting Moieties for Optimal Drug Properties
3:30 pm Bicycle Radionuclide Conjugates Targeting Novel Antigens for Radioisotope Delivery into Solid Tumors
Synopsis
- Outlining the proprietary Bicycle® screening platform can identify novel peptidic binders to complex targets that lack pre-existing peptide-based ligands and then convert these into high affinity and selective Bicycle® molecules
- Revealing development of Bicycle radionuclide conjugates (BRCs) targeting MT1-MMP and EphA2
- Sharing preclinical data from proteins that are widely expressed in a variety of cancers with high unmet medical need
4:00 pm Roundtable Discussion: Assessing Targeting Moieties to Match Target & Disease Characteristics
Synopsis
- Evaluating isotope half-life and desired circulation time
- Exploring varying options for targeting: small molecule, peptide, antibody, engineered antibodies, antibody fragments, mini proteins and more
- Appreciating differences in potential toxicities with each approach